NCT01871194View on ClinicalTrials.gov

An Observational Post-Authorization Safety Specialist Cohort Event Monitoring Study (SCEM) to Monitor the Safety and Utilization of Rivaroxaban (Xarelto®).

CompletedOBSERVATIONAL
Enrollment

3,400

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

January 31, 2016

Study Completion Date

September 30, 2017

Conditions
Atrial FibrillationDeep Vein ThrombosisPulmonary Embolism
Trial Locations (1)

SO31 1AA

Drug Safety Research Unit, Southampton

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Professor Saad Shakir

OTHER

NCT01871194 - An Observational Post-Authorization Safety Specialist Cohort Event Monitoring Study (SCEM) to Monitor the Safety and Utilization of Rivaroxaban (Xarelto®). | Biotech Hunter | Biotech Hunter